Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
15.5
% (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFiscal year ending March 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥54,353 million+15.5%
Operating profit¥5,783 million+8.2%
Net income¥2,854 million-8.9%
Results for the three months of the current quarter
Revenue
¥14,183 million
EBITDA
¥2,384 million
Full-year earnings forecast
Fiscal year ending March 2027
Revenue
¥64,600 million
EBITDA
¥9,700 million
Operating profit
¥3,800 million
Profit for the period attributable to owners of the parent
¥1,100 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue is expected to fall short of the full-year plan, while operating profit is expected to exceed the full-year planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue (year on year, excluding medical care residences)
Beginning of the period
¥43,476 million
Medical institutions in Japan-450
Medical institutions overseas-253
Hospice2,726
Home-Visit Nursing536
Other104
End of period
¥46,649 million
EBITDA (year on year, excluding medical care residences)
Beginning of the period
¥7,412 million
Medical institutions in Japan-450
Medical institutions overseas-253
Hospice373
Home-Visit Nursing275
Other-99
End of period
¥7,166 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
Actual results for the fiscal year ending March 2026Approximately ¥151 per U.S. dollar
Forecast for the fiscal year ending March 2027Approximately ¥155 per U.S. dollar
Hospice medical service fee per patientApproximately 24% decline
Rate of revision to core medical service fees+3.09%
New initiatives
- Making Vascular Specialists, LLC a consolidated subsidiary
- Establishing a new company with Boston Medical Science株式会社 for remote radiology interpretation support services
- Establishing a medical and nursing care systems development company, 『株式会社シーユーシーミー』
- Monetizing 3 business-use properties and investing approximately ¥4,050 million of the sale proceeds in new growth areas
Key KPIsA metric the company considers important as a management benchmark.
- Quarterly revenue¥14,183 millionYear on year against the same period last yearNew record high
- Number of hospice facilities63 FacilityYear on year against the same period last year+23.5%
- Hospice capacity2,225 peopleYear on year against the same period last year+27.7%
- Number of U.S. patients249,726 peopleYear on year against the same period last year+2.3%
- Number of home-visit nursing users15,057 peopleYear on year against the same period last year+3.8%
- Total home-visit nursing care hours1,275 Thousand hoursYear on year against the same period last year+4.5%
- Full-time equivalent nurses and therapists1,205 peopleYear on year against the same period last year+4.7%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
United States
Number of patients
249,726 people+2.3%
Revenue per patient
¥26,821-2.3%
Hospice
Annual revenue per resident
¥8.6 million-4.5%
Medical Care Residences
Annual revenue per resident
¥4.9 million
Segment results
Medical institutions
Revenue
¥17,312 million-1.7%
EBITDA
¥3,958 million
Operating profit
¥4,555 million
Hospice
Revenue
¥16,714 million+21.5%
EBITDA
¥2,244 million+11.4%
Operating profit
¥980 million
Home-Visit Nursing
Revenue
¥12,949 million+5.2%
EBITDA
¥1,827 million+10.7%
Operating profit
¥1,416 million
Medical Care Residences
Revenue
¥7,704 million
EBITDA
¥1,349 million
Operating profit
¥-262 million
Medium-term management plan targets
Number of hospice facilities opened
Fiscal year ending March 20278
Fiscal year ending March 2028Opening schedule undecided
Hospice capacity
Fiscal year ending March 20273,253
Fiscal year ending March 20283,253
Number of stores and locations
Number of key locations supporting medical institutions in Japan
End of period162 Location
Change during the period8 new locations opened
Number of hospice facilities
End of period63 Facility
Change during the period12 new facilities opened, including facilities opened by the company and other facilities
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥54,353 million (YoY +15.5%) |
| Operating profit | ¥5,783 million (YoY +8.2%) |
| Net income | ¥2,854 million (YoY -8.9%) |
| Results for the three months of the current quarter | Revenue ¥14,183 million / EBITDA ¥2,384 million |
| Full-year earnings forecast | Fiscal year ending March 2027 Revenue ¥64,600 million / EBITDA ¥9,700 million / Operating profit ¥3,800 million / Profit for the period attributable to owners of the parent ¥1,100 million |
| Self-assessment against the plan | Revenue is expected to fall short of the full-year plan, while operating profit is expected to exceed the full-year plan |
| Segment results | Medical institutions Revenue ¥17,312 million (YoY -1.7%) / EBITDA ¥3,958 million / Operating profit ¥4,555 million / Hospice Revenue ¥16,714 million (YoY +21.5%) / EBITDA ¥2,244 million (YoY +11.4%) / Operating profit ¥980 million / Home-Visit Nursing Revenue ¥12,949 million (YoY +5.2%) / EBITDA ¥1,827 million (YoY +10.7%) / Operating profit ¥1,416 million / Medical Care Residences Revenue ¥7,704 million / EBITDA ¥1,349 million / Operating profit ¥-262 million |
| Breakdown of Factors Affecting the Change | Revenue (year on year, excluding medical care residences) Beginning of the period ¥43,476 million / Medical institutions in Japan -450 / Medical institutions overseas -253 / Hospice 2,726 / Home-Visit Nursing 536 / Other 104 / End of period ¥46,649 million / EBITDA (year on year, excluding medical care residences) Beginning of the period ¥7,412 million / Medical institutions in Japan -450 / Medical institutions overseas -253 / Hospice 373 / Home-Visit Nursing 275 / Other -99 / End of period ¥7,166 million |
| Key KPIs | Indicator name Quarterly revenue / Value ¥14,183 million / Year on year against the same period last year New record high, Indicator name Number of hospice facilities / Value 63 Facility / Year on year against the same period last year 23.5 Facility, Indicator name Hospice capacity / Value 2,225 people / Year on year against the same period last year 27.7 people, Indicator name Number of U.S. patients / Value 249,726 people / Year on year against the same period last year 2.3 people, Indicator name Number of home-visit nursing users / Value 15,057 people / Year on year against the same period last year 3.8 people, Indicator name Total home-visit nursing care hours / Value 1,275 Thousand hours / Year on year against the same period last year 4.5 Thousand hours, Indicator name Full-time equivalent nurses and therapists / Value 1,205 people / Year on year against the same period last year 4.7 people |
| Unit price and quantity metrics | United States Number of patients 249,726 people (YoY +2.3%) / Revenue per patient ¥26,821 (YoY -2.3%) / Hospice Annual revenue per resident ¥8.6 million (YoY -4.5%) / Medical Care Residences Annual revenue per resident ¥4.9 million |
| Number of stores and locations | Number of key locations supporting medical institutions in Japan End of period 162 Location / Change during the period 8 new locations opened / Number of hospice facilities End of period 63 Facility / Change during the period 12 new facilities opened, including facilities opened by the company and other facilities |
| Assumptions Underlying the Business Outlook | Exchange rate Actual results for the fiscal year ending March 2026 Approximately ¥151 per U.S. dollar / Forecast for the fiscal year ending March 2027 Approximately ¥155 per U.S. dollar / Hospice medical service fee per patient Approximately 24% decline / Rate of revision to core medical service fees +3.09% |
| Medium-term management plan targets | Number of hospice facilities opened Fiscal year ending March 2027 8 / Fiscal year ending March 2028 Opening schedule undecided / Hospice capacity Fiscal year ending March 2027 3,253 / Fiscal year ending March 2028 3,253 |
| New initiatives | Making Vascular Specialists, LLC a consolidated subsidiary, Establishing a new company with Boston Medical Science株式会社 for remote radiology interpretation support services, Establishing a medical and nursing care systems development company, 『株式会社シーユーシーミー』, Monetizing 3 business-use properties and investing approximately ¥4,050 million of the sale proceeds in new growth areas |
Items this document does not state (15)
Ordinary incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesProgress against full-year forecastNumber of employeesRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as hospice facilities and medical care residences expanded. Operating profit increased due to a ¥1,441 million gain on the sale of 3 business-use properties in connection with their asset monetization. Profit attributable to owners of the parent declined as the ¥285 million foreign exchange gain related to the collection of a loan to a U.S. subsidiary, which was recorded in the previous fiscal year, was no longer recognized.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.